The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

May 21 () - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's ...

Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.

Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...

Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...

This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...

(Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ ...

EU regulators backed the combo based on strong Phase 3 data showing improvements across survival and tumor response outcomes.